Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: post hoc analysis of the Irbesartan Diabetic Nephropathy Trial | Zendy

Marc Evans | Zendy; Stephen C. Bain | Zendy; Simon Hogan | Zendy; Rudy Bilous | Zendy

Open Access

Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: post hoc analysis of the Irbesartan Diabetic Nephropathy Trial

Author(s) -

Marc Evans,

Stephen C. Bain,

Simon Hogan,

Rudy Bilous

Publication year - 2011

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gfr696

Subject(s) - irbesartan , medicine , renal function , diabetic nephropathy , post hoc analysis , urology , diabetes mellitus , nephropathy , kidney disease , endocrinology , blood pressure

The Irbesartan Diabetic Nephropathy Trial (IDNT) demonstrated that irbesartan significantly slowed established Type 2 diabetic nephropathy progression. Estimated glomerular filtration rate (eGFR), now widely used to monitor chronic kidney disease (CKD) progression, was not previously examined in IDNT. This post hoc analysis aimed to confirm IDNT results using eGFR as principal outcome measure.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research